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Abstract
BACKGROUND: Deregulation of c-myc plays a major
role in the carcinogenesis of human malignancies.
We investigated the amplification of the c-myc gene in
a surgical series of Barrett cancers. METHODS: Pri-
mary resected esophageal (Barrett) adenocarcinomas
(n = 84) were investigated for c-myc amplification using
chromogene in situ hybridization. Tumor samples were
assembled in a tissue microarray. c-myc gene dosage
was correlated with clinicopathologic parameters,
including the survival and gene expression of cyclo-
oxygenases (COX-1 and COX-2) and proangiogenic
growth factors (VEGF-A and VEGF-C). RESULTS: The
majority (70 of 84; 83.3%) exhibited amplification of
the c-myc gene. There were low-level amplifications
in 63 (75.0%) cases and high-level amplifications in
7 (8.3%) cases. No amplificationwas found in 14 (16.7%)
cases. Tumors without c-myc amplification had lower
VEGF-A, VEGF-C, and COX-2 expression levels than
tumors with low-level and high-level c-myc amplifi-
cation (statistically significant for VEGF-A; P = .0348).
c-myc amplification was not correlated with clinicopa-
thological parameters or survival. Only diffuse and
mixed-type tumors, according to Lauren classification,
exhibited c-myc amplifications more frequently (P =
.0466). CONCLUSIONS: Amplifications of the c-myc
gene are frequent in Barrett cancer. c-myc may be in-
volved in the regulation of angiogenesis.
Neoplasia (2006) 8, 702–707
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Introduction
Barrett cancers comprise an entity of increasing clinical
importance due to a vastly unexplained rapid rise in inci-
dence in recent decades [1,2]. Chances for cure are still
limited to surgical resection at an early stage of the disease
[3,4]. Histologically, these esophageal tumors are adeno-
carcinomas arising in the distal esophagus within the pre-
cancerous Barrett esophagus, which is defined as a
metaplastic change of the normal esophageal squamous
mucosa [2]. Malignant progression is driven by the chronically
damaging effect of gastroesophageal reflux, which promotes a
characteristic histopathologic sequence, from specialized in-
testinal metaplasia to low-grade and high-grade intraepithelial
neoplasia to invasive adenocarcinoma [2]. Despite intensive
research, knowledge about molecular mechanisms underlying
Barrett cancer is still rather limited [5].
The proto-oncogene c-myc (‘‘cellular myomatosis onco-
gene’’) encodes a transcription factor that is regarded es-
sential for progression in human malignancies. It is located at
the chromosomal region 8q23–24 [6]. The c-myc gene has also
been implicated in Barrett carcinogenesis. Amplification of the
gene c-myc [7,8], as well as overexpression of the c-myc
oncoprotein [9], has been demonstrated in invasive Barrett
adenocarcinomas, but with great variability (Table 1). Investi-
gations of precursor lesions (high-grade intraepithelial neo-
plasia, which has been previously addressed as ‘‘dysplasia’’)
[10] have suggested that c-myc dysregulation by amplification is
an early event during Barrett carcinogenesis [7–9] because it is
frequently found also in precursor lesions of esophageal ade-
nocarcinoma, especially of high-grade intraepithelial neoplasia.
c-myc has been implicated in various cellular processes,
including cell growth, proliferation, loss of differentiation, apop-
tosis [11,12], and regulation of angiogenesis [13]. Angiogenesis
is regarded as an essential feature of malignant tumors. Only
recently, we have demonstrated the importance of pro-
angiogenic factors (VEGF-A and VEGF-C) and their regulation
by the prostaglandin biosynthetic pathway (COX-1 and COX-2)
in Barrett cancer [14].
It has been estimated that c-myc is associated with poor
prognosis and has been, therefore, suggested as a clinically
relevant marker [12]. This has been shown for c-myc expres-
sion in colorectal carcinomas [15]. Moreover, inactivation of
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c-myc, or downstream targets of c-myc, might provide impor-
tant therapeutic targets [16].
Study Aims
We have investigated the frequency of c-myc amplification
in a large series of primary resected Barrett cancers using
chromogene in situ hybridization (CISH). We aimed at
the following:
 To clarify controversial results on the frequency of c-myc
amplifications, with previous studies reporting different
results in this respect [7,8], using a highly sensitive CISH
method
 To elucidate whether c-myc amplification is correlated with
the expression of genes involved in angiogenesis, which
we have investigated previously in a subset of tumors
included in the current study [14]
 To analyze the correlation of c-myc amplifications with
clinicopathological parameters, including survival.
Materials and Methods
Patients
One hundred thirty-seven primary resected esophageal
adenocarcinomas arising in association with Barrett epithe-
lium were investigated. Due to technical reasons associated
with CISH (described below), only 84 cases were eligible for
the final analysis. Patient and tumor characteristics, such
as age, gender, tumor size, pT/pN/pL category, Union Inter-
nationale Contre le Cancer (UICC) stage [17], and Lauren
classification and grading [10], are included in Table 2.
All patients had undergone primary surgical resection
(radical transthoracic or transhiatal esophagectomy with
lymphadenectomy) at the Technical University of Munich
between 1991 and 2003. None of these patients had re-
ceived prior antineoplastic therapy (neither chemotherapy
nor radiochemotherapy). Patients’ approval was secured
according to local arrangements by the ethics committee.
This study was performed with patients’ consent allowing
molecular research to be performed on specimen obtained
during surgical resection.
Tissue Array
The tumor tissues of the 137 esophageal adenocarcino-
mas under analysis were assembled in tissue microarrays.
Core needle biopsies were retrieved from original tumor
blocks using a manual arrayer (Beecher Instruments, Sun
Table 1. Frequency of c-myc Amplification/Overexpression in Barrett Adenocarcinomas Based on Available Literature.
Publication n Method Frequency of c-myc Amplification/Overexpression
Investigation of the amplification of the c-myc gene in the 8q23 chromosomal region
Miller et al. [8] 87 Southern blot analysis 4 of 87 (4.6%)
Sarbia et al. [7] 43 Differential PCR 17 of 39 (43.6%)
Arnould et al. [18] 15* Comparative genomic hybridization (CGH) Gain of 8q24 in 8 of 15 cases (53.3%)
Bhargava et al. [19] 28y CGH Gain of 8q in 79% recurrent high-level amplifications
of 8q23–24.1 in > 10%
Walch et al. [6] 30 CGH High-level amplification of 8q23–24 in 24 of 30 cases (80%)
Current investigation 84 CISH 70 of 84 (83.3%)
Investigation of c-myc protein overexpression
Tselepis et al. [9] 20 Western blot analysis 18 of 20 (90%)
*Adenocarcinomas of the esophagus or gastroesophageal junction. No further information is given in the paper. Thus, this paper does not deal with pure Barrett
cancer collective data.
yOnly 11 adenocarcinomas of the distal esophagus. The remaining 17 tumors under investigation were adenocarcinomas located at a lower level of the
esophagogastric junction (not Barrett cancers).
Table 2. Level of c-myc Amplification in the Whole Population (n = 84 Eligible
















84 14 (16.7) 63 (75.0) 7 (8.3)
Subgroups
Age (years)
< 64 45 6 (13.3) 34 (75.6) 5 (11.1) ns
> 64 39 8 (20.5) 29 (74.4) 2 (5.1)
Sex
Male 78 14 (18.0) 57 (73.1) 7 (9.0) ns
Female 6 0 6 (100.0) 0
Tumor size* (mm)
< 50 52 7 (13.5) 38 (75.0) 6 (11.5) ns
> 50 32 6 (18.8) 25 (78.1) 1 (3.1)
Depth of invasion (pT category)
pT1/2 47 8 (9.5) 34 (40.5) 5 (6.0) ns
pT3/4 37 6 (7.1) 29 (34.5) 2 (2.4)
Lymph node involvement (pN category)
pN0 40 8 (20.0) 28 (70.0) 4 (10.0) ns
pN1 44 6 (13.6) 35 (79.6) 3 (6.8)
Lymphatic vessel invasion (L category)
L0 59 11 (18.6) 45 (76.3) 3 (5.1) ns
L1 25 3 (12.0) 18 (72.0) 4 (16.0)
UICC stage
I/II 55 9 (16.4) 40 (72.7) 6 (10.9) ns
III/IV 29 5 (17.2) 23 (79.3) 1 (3.5)
Differentiation (grade)
G1/2 41 6 (14.6) 33 (80.5) 2 (4.9) ns
G3/4 43 8 (18.6) 30 (69.8) 5 (11.6)
Lauren classification
Diffuse 2 0 1 (50.0) 1 (50.0) .0466
Intestinal 74 14 (18.9) 56 (75.7) 4 (5.4)
Mixed 8 0 6 (75.0) 2 (25.0)
*Size range: 5 to 130 mm.
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Prairie, WI) and positioned in a recipient paraffin array block.
Viable representative areas of tumor specimens were
marked by an experienced pathologist (M.S.). At least three
tissue cylinders with a diameter of 0.6mmwere obtained from
each tumor block.
CISH
Four- to 5-mm-thick sections were cut from microarray
paraffin blocks and dewaxed with xylene, and then re-
hydrated with 100% ethanol and water. Target retrieval and
enzyme digestion were achieved using a commercially avail-
able tissue pretreatment kit (no. 00-8401; from Zymed Lab-
oratories, distributed through Zytomed, Berlin, Germany).
The sections were dehydrated in upgrading ethanol series
and air-dried. Fifteenmicroliters of digoxigenin-labeled c-myc
probe (84-1700; from Zymed Laboratories, distributed
through Zytomed) was applied on the microarray section,
enclosed by a coverslip, sealed, and codenatured on a hot
plate (Hybrite; from Vysis, distributed through Abbott, Wies-
baden, Germany) for 5 minutes at 94jC. Hybridization was
performed overnight at 37jC. Then, the coverslip was re-
moved by soaking in standard saline citrate (SSC) solution
at room temperature and washed in SSC for 5 minutes at
75jC. The remaining hybridized probe linked to digoxigenin
was detected by mouse antidigoxigenin antibody followed
by polymerized horseradish peroxidase–goat antimouse
immunoglobulin. Peroxidase was developed with diamino-
benzidine, and nuclei were counterstained with hematoxylin.
All detection reagents were provided in commercially avail-
able kits (Spotlight CISH Polymer Detection Kit, 84-9246;
from Zymed Laboratories, distributed through Zytomed).
The interpretation of CISH results was performed by a
senior pathologist (M.S.) with a light microscope using a40
objective (original magnification, 400; Figure 1, A and B).
Signals were seen as nuclear dark brown dots. Fifty to
100 nonoverlapping tumor cell nuclei were evaluated per
sample. A gene copy number of one to five copies per nucleus
was scored as ‘‘no amplification’’ (Figure 1A). A gene copy
number of 6 to 10 copies per nucleus in at least 50% of
cancer cells was considered ‘‘low-level amplification.’’ A gene
copy number of more than 10 copies per nucleus or the
presence of clusters in at least 50% of cancer cells was
considered as ‘‘high-level amplification’’ (Figure 1B) [18,19].
Non-neoplastic cells in tissues were always evaluated as in-
test quality controls.
Due to various reasons (i.e., loss of tissue cores during
hybridization procedures, lack of hybridization, or lack of
viable tumor tissues in tissue cores), only 84 of the initial
137 esophageal adenocarcinoma cases could finally be
assessed for c-myc gene dosage.
Results
c-myc gene amplification was assessed using tissue arrays
that included 137 esophageal adenocarcinomas. Due to
various technical reasons (i.e., loss of tissue cores during
hybridization procedures, lack of hybridization, or lack of
viable tumor tissue in tissue cores), only 84 of the initial
137 esophageal adenocarcinoma cases could be finally as-
sessed for c-myc gene dosage. The majority of cases (70 of
84; 83.3%) exhibited amplification of the c-myc gene. These
were low-level amplifications in 63 (75.0%) cases and high-
level amplifications in 7 (8.3%) cases. No amplification was
found in 14 (16.7%) cases (Table 2).
Subgroup analysis according to clinicopathological pa-
rameters (Table 2) did not show any statistically significant
differences with respect to c-myc amplification (patient age,
sex, tumor size, pT/pN category, lymphatic vessel invasion,
UICCstage, and tumor grade), except for Lauren classification
(P = .0466). Thus, none of the diffuse or mixed-type tumors
according to Lauren classification lacked c-myc amplifica-
tions. Six (75.0%) of eight mixed-type tumors under investiga-
tion and one (50.0%) of two diffuse-type tumors exhibited
low-level amplifications of the c-myc gene. Furthermore, two
(25.0%) of eight mixed-type tumors and one (50.0%) of two
diffuse-type tumors showed high-level amplifications of c-myc.
Figure 1. (A) Cells of a moderately differentiated adenocarcinoma (center and bottom) with a maximum of five nuclear brown dots (arrows indicate nuclei)
indicating no evidence of c-myc gene amplification (original magnification, 600). (B) In contrast, another moderately differentiated adenocarcinoma (bottom left)
with more than 10 dots per nucleus (arrows indicate nuclei) indicating high-level amplification of the c-myc gene (original magnification, 600). Adjacent stromal
cells show no evidence of c-myc gene amplification (asterisk).
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Survival analysis according to the univariate Kaplan-Meier
method did not show any significant impact of c-myc ampli-
fication on patients’ survival (Figure 2).
In a subset of tumors under analysis (n = 51), data on the
mRNAexpression of four genes [i.e. cyclooxygenases (COX-1
andCOX-2) and proangiogenetic growth factors (VEGF-A and
VEGF-C), which were determined in a previous investigation]
[14] were available. Correlation analysis showed that tumors
without c-myc amplification tended to have lower COX-2,
VEGF-A, and VEGF-C mRNA expression levels than tumors
with low-level amplification, which had lower expression levels
compared to cases with high-level amplification (Table 3).
This trend toward increased gene expression with increasing
level of c-myc amplification was statistically significant for
VEGF-A (P = .0466; chi-square analysis).
Discussion
According to our current investigation, amplification of the
c-myc gene is frequent in esophageal adenocarcinomas.
However, the majority of cases showed low-level amplifica-
tions (75% of the cases), whereas only a minority of the
tumors (7.3%) showed high-level amplifications. Only at first
glance do these findings contradict existing data in the
literature (Table 1). Thus, Miller et al. [8], investigating a
series of similar size (87 Barrett cancers) for c-myc amplifi-
cation, found amplification of c-myc in only 4 (4.6%) cases.
However, this discrepancy can be well explained by the fact
that Miller et al. used Southern blot analysis, which has a
considerably lower sensitivity than CISH. In contrast, com-
parative gene expression data have also shown that genetic
gains are frequent at 8q.23–24, the chromosomal region
where c-myc is localized (Table 1). Walch et al. [6] demon-
strated high-level amplification of the region in 80% (24 of
30) Barrett cancer cases. Moskaluk et al. [20] found gains
of 8q24 in 53.3% (8 of 15) cases, whereas van Dekken et al.
[21] found gains of 8q in 79%. However, the results of the
latter two studies have to be interpreted with caution because
the tumors under investigation were not exclusively Barrett
cancers (see Table 1 and footnotes). Adenocarcinomas of
the esophagogastric junction, which have been included in
these studies, are known to share more similarities with
gastric cancers, which are known to exhibit c-myc amplifica-
tion quite frequently.
A polymerase chain reaction (PCR)–based investigation
found c-myc amplifications in 43.6% (17 of 39 Barrett cancer
cases under investigation) [7]. Although these results are
more similar to the findings of our current investigation, this
PCR approach is, again, inferior to CISH. A third study, in
which overexpression of the c-myc oncoprotein was studied
by Western blot analysis, revealed a high level of tumors
overexpressing c-myc (18 of 20 cases; 90%). All these data
Figure 2. c-myc amplifications did not significantly affect outcome after the resection of Barrett cancer (univariate survival analysis according to the Kaplan-
Meier method).
Table 3. Correlation of c-myc Amplification Data with Relative mRNA Ex-
pression Levels of COX-1, COX-2, VEGF-A, and VEGF-C, as Determined by











Mean 51 12.18 13.65 9.36 ns
SD 16.03 23.48 4.73
Median 8.13 3.85 9.51
Min 0.05 0.01 3.57
Max 49.47 108.11 15.57
COX-2
Mean 51 12.98 24.36 27.03 ns
SD 13.96 42.87 19.77
Median 6.22 10.14 16.15
Min 0.82 0.05 7.37
Max 39.25 259.63 59.32
VEGF-A
Mean 51 3.22 7.93 9.841 .0348
SD 3.29 15.92 7.92
Median 2.88 3.71 7.78
Min 0.08 0.08 1.88
Max 11.99 104.57 22.80
VEGF-C
Mean 51 0.06 0.08 0.15 ns
SD 0.08 0.17 0.11
Median 0.01 0.00 0.14
Min 0.00 0.00 0.01
Max 0.22 1.14 0.36
*The number of cases varies according to the eligibility of available infor-
mation (CISH and gene expression analysis with TaqMan).
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suggest that c-myc is an important molecular feature of inva-
sive Barrett cancers, and especially low-level amplifications
can frequently be foundwhena sensitive technique is applied.
c-myc amplifications have previously been shown to be
less frequent or absent in precursor lesions (non-neoplastic
Barrett esophagus and high-grade intraepithelial neoplasia)
than in invasive Barrett cancer [7,8]. This might explain the
lack of correlation of our results (obtained from invasive
Barrett cancer specimens) with clinicopathological parameters
such as pT/pN category, UICC stage (Table 2), and survival
(Figure 2). Furthermore, this supports the concept that c-myc
amplification is an early event during Barrett carcinogenesis,
as indicated by previously published investigations [6–8].
The association of c-myc amplification with VEGF-A ex-
pression in the current investigation is well in accordancewith
the current understanding of the function of c-myc. Apart from
various other effects by which c-myc contributes to carcino-
genesis (i.e., promotion of cell growth, proliferation, loss
of differentiation, and apoptosis) [12], the gene is also sus-
pected to be involved in the regulation of angiogenesis
[12,13]. c-myc deficiency is a lethal condition that has been
shown to be due to the associated profound defects of
vasculogenesis [13]. Embryos of c-myc/mice lack virtually
the whole the vasculature. These defects can partially be
addressed by the substitution of VEGF, suggesting that
c-myc regulates angiogenesis through VEGF. This result
has been substantiated by further studies indicating that
Myc activation is a sufficient trigger to increaseVEGF expres-
sion [12]. Our results in Barrett cancer (significant correlation
of gene expression level with level of c-myc amplification)
also support this link between c-myc and angiogenesis
through the proangiogenic growth factor VEGF-A.
Due to a variety of implications in carcinogenesis, c-myc
has been suggested as a promising target for molecular
therapies [16]. Although these approaches are still in their
infancy, promising strategies, including the application of
antisense oligodeoxynucleotides, have been suggested to
reduce c-myc expression. One other approach, specifically
referring to the pathophysiology of Barrett carcinogenesis,
relates to the reported modulation of c-myc expression by the
contents of gastroesophageal refluxate. In vitro (cell culture)
and in vivo (reflux models in animals) experiments have
shown that bile acids activate c-myc [22]. Therefore, it was
postulated that preventing esophageal epithelium from
coming into contact with bile acids is one strategy against
Barrett cancer [23]. Prevention of c-myc activation must be
considered as one major aspect of such a strategy.
Conclusion
Our results of frequent (low-level and high-level) c-myc gene
amplifications in a majority of Barrett cancers support the
previously suggested importance of c-myc in this entity.
c-myc amplification is likely to be an early event during Barrett
carcinogenesis. Furthermore, our data suggest that an effect
of the targeting of this gene is, at least in part, antiangiogenic
in nature.
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